

Ellen M. Buettner | Chief Executive Officer

J. Kevin Stitt | Governor

OHCA 2024-15

July 25, 2024

RE: Hospital Provision Emergency Opioid Antagonist

Dear Provider,

As directed by Senate Bill 712 of the 2023 legislative session and Title 63 Oklahoma Statute § 1-706.21, hospitals are required to distribute opioid antagonists to any individual who presents to an emergency department with symptoms of an opioid overdose, opioid disorder, or any other adverse opioid event related to opioid use. For SoonerCare members, separate reimbursement for opioid antagonists is now available for hospitals providing these medications in the emergency department and upon discharge from inpatient care.

Rule revisions at OAC 317:30-5-42.7 and 317:30-5-47 were promulgated through the emergency rulemaking process and made effective March 27, 2024. The rules are currently viewable on the Oklahoma Health Care Authority's policy page. If applicable, please forward this letter to your administrative, billing and compliance departments.

The following HCPCS codes are to be utilized for billing purposes:

- G1028 TAKE-HOME SUPPLY OF NASAL NALOXONE; 2-PACK OF 8MG PER 0.1 ML NASAL SPRAY
- G2215 TAKE-HOME SUPPLY OF NASAL NALOXONE; 2-PACK OF 4MG PER 0.1 ML NASAL SPRAY

The agency appreciates your support and participation in initiatives that educate our members on the life-saving potential of emergency opioid antagonists. OHCA encourages you to review the rule changes in their entirety.

If you have any questions regarding these rule changes, please call the OHCA provider helpline at 800-522-0114. Thank you for the services you provide to SoonerCare members.







Sincerely,

Traylor Rains

State Medicaid Director